EGFR and anemia: Grade > 3 toxicities included rash (10.6%), paronychia (4.3%), diarrhea (6.4%), fatigue (4.3%), mucositis/stomatitis (4.3%), liver function disorder (14.9%), hypertension (19.1%), proteinuria (12.8%) in bevacizumab plus continuous EGFR-TKI group and diarrhea (5.1%), fatigue (7.7%), nausea/vomiting (2.6%), mucositis/stomatitis (2.6%), liver function disorder (5.1%), hypertension (25.6%), leukopenia (51.3%), neutropenia (53.8%), anemia (15.4%), thrombocytopenia (5.1%) in bevacizumab plus chemotherapy group.